Biomarin Pharmaceutical (BMRN) Accumulated Expenses (2010 - 2019)

Biomarin Pharmaceutical (BMRN) has 10 years of Accumulated Expenses data on file, last reported at $46.1 million in Q1 2019.

• Quarterly Accumulated Expenses rose 285.56% year-over-year to $46.1 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $46.1 million (up 285.56% YoY) and the FY2018 annual result came in at $149.9 million, up 6.5% from the prior year.
• Accumulated Expenses retreated to $46.1 million in Q1 2019, from $149.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $179.3 million in Q4 2015 to a low of $12.0 million in Q1 2018.
• A 5-year average of $87.2 million and a median of $80.6 million in 2017 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2015 — Accumulated Expenses soared 3541.23% — and 2018, when it tumbled 80.24%.
• Tracing BMRN's Accumulated Expenses over 5 years: stood at $179.3 million in 2015, then slumped by 39.18% to $109.0 million in 2016, then increased by 29.11% to $140.8 million in 2017, then increased by 6.5% to $149.9 million in 2018, then sank by 69.25% to $46.1 million in 2019.
• The last three Accumulated Expenses figures came in at $46.1 million (Q1 2019), $149.9 million (Q4 2018), and $177.4 million (Q3 2018), per Business Quant data.